drugset / Trial / NCT06775834

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

NCT06775834

Phase 1 Completed 24 enrolled Shandong Suncadia Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to evaluate pharmacokinetics of HRS-1893 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.

Timeline

Start
2025-02-11
Primary completion
2025-07-23
Completion
2025-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-1893 Unknown